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The present study involves preparation and characterization of a combination tablet of ranitidine in 
immediate release form and domperidone in sustained release form, using ion exchange resins. Ranitidine 
lowers acid secretion, while domperidone release over a prolonged period improves gastric motility 
thus justifying this combination in gastro esophageal reflux diseases (GERD) and ensuring patient 
compliance.  Drug loading was carried out by batch method & resinates were characterized using FTIR, 
XRPD. Resinates were formulated as a combination tablet and evaluated for tablet properties & in vitro 
drug release. Resinates provided sustained release of domperidone and immediate release of ranitidine. 
IR and X-ray studies indicate complexation of drug and resin along with monomolecular distribution 
of drugs in amorphous form in the resin matrix. The tablets of resinate combination showed good tablet 
properties. In-vitro drug release gave desired release profiles and ex-vivo drug absorption studies carried 
out by placing everted rat intestine in dissolution medium indicated statistically significant similarity in 
absorption from test and marketed formulation. The novelty of this study is that the retardation in release 
of domperidone from resinates is achieved by presence of weak resin in the formulation. 
Uniterms: Drugs/delivery system. Ranitidine/tablets/immediate release. Domperidone/tablets/sustained 
release. Tablets/delivery system. Ion exchange resins/use/ drugs delivery system.
O presente estudo envolve a preparação e a caracterização de associação do comprimido de ranitidina de 
liberação imediata e domperidona de liberação prolongada, utilizando resinas de troca iônica. A ranitidina 
diminui a secreção ácida, enquanto a liberação prolongada de domperidona melhora a motilidade gástica, 
justificando, dessa forma, a associação em doenças de refluxo gastroesofágico (DRGE) e garantindo a 
adesão do paciente. A carga de fármaco foi efetuada pelo método em batelada e os resinatos, caracterizados 
utilizando-se FTIR e XRPD. Os resinatos foram formulados como comprimido da associação e avaliados 
com relação às propriedades dos comprimidos e liberação do fármaco in vitro. Os resinatos proporcionaram 
a liberação prolongada da domperidona e a liberação imediata da ranitidina. IV e estudos de difração de 
raios X indicaram a complexação do fármaco e da resina junto com a distribuição monomolecular dos 
fármacos, em estado amorfo, na matriz da resina. Os comprimidos da associação do resinato apresentaram 
boas propriedades. Obtiveram-se os perfis de liberação in vitro e os estudos de absorção dos fármacos 
ex vivo realizados com intestino de rato em meio de dissolução indicaram semelhança significativa na 
absorção entre as formulações teste e comercializada. A inovação do trabalho é que o retardamento da 
liberação da domperidona dos resinatos é atingido pela presença de resina fraca na formulação. 
Unitermos: Fármacos/sistema de liberação. Ranitidina/comprimido/liberação imediata. Domperidona/
comprimido/liberação prolongada. Comprimidos/sistema de liberação. Resinas de troca inônica/uso/
liberação de fármacos.
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INTRODUCTION
Research over the past few years has revealed that 
ion exchange resins are equally suitable for drug delivery 
technologies, including controlled release, site-specific 
fast dissolving, iontophoretically-assisted transdermal, 
nasal, topical, and taste masked systems. (Borodkin et 
al.,1971). Literature review (Anand et al., 2001) A litera-
ture review (Anand et al., 2001) revealed that ion exchange 
resins have versatile properties as a drug delivery vehicle. 
Moreover, resin characteristics such as acid or base strength, 
porosity, degree of cross linkage and particle size can be 
chosen from among the many available ion exchange resins 
to achieve the intended purpose (Vimaladevi et al., 2001). 
Combination products have the advantages of combina-
tion therapy besides reducing the complexity of the dosage 
regimen. Thus, combination therapy, if used optimally, has 
the advantages of increased efficacy and improved clinical 
effectiveness, broadening the array of therapeutic options, 
offering customization of the treatment to suit specific 
patient needs, enhanced patient adherence and reduction 
in cost of administration. (Wetheimer et al., 2002). Gastro 
esophageal reflux disease (GERD), reflux esophagitis, 
Peptic ulcer, gastric ulcer and other gastric acid-related 
disorders have pathogenesis related to reduced gastric 
motility and release of excessive gastric acid. GERD and 
gastric ulcer have been successfully treated with a range 
of gastric acid inhibitors, such as ranitidine, which are acid 
suppressing agents. Stimulation of gastric motility has 
been proposed to accelerate the healing of gastric ulcer 
and prokinetic agents such as domperidone are known to 
enhance gastrointestinal motility and prevent duodenogas-
tric reflux. The aim of combining two or more drugs with 
complementary modes of action using ion exchange resins 
is to produce the desired release pattern and therapeutic 
benefits along with the advantage of reducing the complex-
ity of the dosage regimen thus leading to patient compli-
ance (Norris et al., 2005). In the present study, sustained 
release of domperidone was achieved by complexing with 
Indion 244 while the immediate release form of ranitidine 
hydrochloride was prepared by complexing with Indion 
294. In vitro drug release from resinates was studied. Res-
inates were formulated into combination tablets and tablets 
were evaluated for hardness, thickness, friability, weight 
variation & in-vitro drug release. An everted rat intestine 
model was employed for studying ex-vivo absorption and 
was compared with marketed preparation. 
EXPERIMENTAL
Material
Ranitidine HCl was a gift from Wockhardt Pharma 
Ltd. Domperidone was from BURGEON Pharmaceuticals 
Pvt. Ltd..  Indion 244, Indion 294 were provided by Ion 
exchange India Ltd. Ranitidine HCL and domperidone 
were analyzed by Jasco V-530 UV/ VIS spectrophotome-
ter.  Resinates were evaluated by Jasco FT/IR-460.
Methods
The ranitidine & domperidone were simultaneously 
estimated by simultaneous equation method spectropho-
tometricaly at 326 nm & 287 nm using Jasco V-530 UV/
VIS Spectrophotometer. 
Drug loading was carried out by batch method des-
cribed elsewhere in the literature. (Vimaladevi et al., 2001; 
Plaizier et al., 1992).
The weak cation exchange resin Indion 234 was 
selected for binding ranitidine as ranitidine is a basic 
drug and is needed in immediate release form, whereas 
Indion 244,  a strong cation exchange resin, was chosen 
to produce sustained release resinates of domperidone, 
again a basic drug. Both the drugs ranitidine hydrochloride 
& domperidone (100 mg each) were separately added to 
100 mL of deionised water, and Indion 294 & Indion 244 
(100 mg each), respectively was placed into the solutions 
and stirred for four hours on a mechanical stirrer. The so-
lutions were filtered and the amount of drug remaining in 
the filtrate was determined spectrophotometrically.
The amount of drug adsorbed was determined by 
the difference between the amount of drug present in 
stock solution and amount remaining in filtrate at the end 
of stirring.
Evaluation of physical properties of resins and 
resonates (Lordi et al., 1991)
Different physical parameters of resinates including 
TABLE I - Properties of Indion 244 and Indion 294
Resin Functionality Matrix Form Ion exchange capacity
Indion 244 -SO
3
H Cross linked polystyrene H+ 4.5 meq/grygm
Indion 294 -COOH Cross linked polyacrylic K+ NA
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shape, flow properties, bulk density, tap density and pa-
cking ability were determined. 
Characterization of resin and resinates 
The FT-IR studies were carried out using a Jasco FT/
IR-460. The X- ray diffraction studies were carried on a 
Phillips analytical X-ray BV(PW 1710) device using cu 
anode 40 kv voltage and 30 ma current. 
In-vitro drug release from resinates:
Resinates of ranitidine hydrochloride with Indion 
294, and domperidone with Indion 244, were subjected to 
in-vitro dissolution studies using an USP type II apparatus 
at 100 rpm. The dissolution medium was 900 ml 0.1 N 
HCl at 37 ± 0.5 ºC.  
In-vitro drug release from combination of resinates:
Resinates of ranitidine hydrochloride and domperi-
done, equivalent to their doses, were combined together. 
The combination of resinates were then subjected to in- 
vitro dissolution studies using an USP type II apparatus 
at 100 rpm. The dissolution medium was 900 ml 0.1 N 
HCl at 37 ± 0.5 ºC.  
Formulation of combination tablets
Resinates of ranitidine HCl (441.17 mg) and dom-
peridone (32.25 mg)  equivalent to the therapeutic dose 
of free drug, were blended with mannitol (71.38 mg) and 
granulated with gelatin solution (10%). The granules were 
dried and blended with sodium starch glycolate (6 mg), 
talc(12 mg), magnesium stearate (6 mg), methyl paraben 
(1.08), and propyl paraben (0.12 mg) as excipients. Total 
weight of each tablet was kept at 600 mg. The tablets were 
compressed on a Karnavati Rimek press, using D tooling 
and a 12.5 mm flat punch with pressure adjusted to achieve 
hardness of 5 kg/cm2 .
Evaluation of prepared tablets (Banker, Anderson, 
1991)
The physical properties of tablets such as general 
appearance, hardness, thickness, friability and weight 
variation, were determined as described elsewhere in the 
literature.
In-vitro drug release profile of combination tablet and 
marketed tablets
Prepared tablets and marketed tablets were subjected 
to in-vitro dissolution studies using an USP type II appa-
ratus at 100 rpm. Dissolution medium was 900 ml 0.1 N 
HCl at 37 ± 0.5 ºC.
Ex-vivo study for absorption through everted rat 
intestine (Dixon et al., 1977; Chowhan, 1977)
Ex-vivo study for absorption of drugs by the everted 
rat intestine technique was carried out using a modified 
perfusion apparatus.
The apparatus consist of ‘U’ shaped glass tubing 
having 1 cm inner diameter with cannulated cut on one 
arm of the ‘U’ tube. The volume capacity of apparatus 
was 25 mL. The distance between two cannulated arms 
was 8 cm where the intestine was tied. After placement of 
intestine on the perfusion apparatus, the apparatus were 
dipped into the dissolution media in the dissolution pan 
and the dissolution study was performed under the above-
mentioned conditions. 
From the prepared tablet, absorption of drugs 
through rat intestine was compared with marketed formu-
lations of domperidone and ranitidine HCl.
RESULT AND DISCUSSION
The batch process was used for drug loading. From 
preliminary experiments, 4 hours was found to be the 
optimum period for attainment of loading equilibrium of 
domperidone & ranitidine. The drug loading was carried 
out at 1:1 drug resin ratio for both drug resin combinations. 
Indion 244 domperidone showed 48.44% & Indion 294 - 
ranitidine showed 40.44% of drug content.
Table II summarizes the physical properties of resins 
and resinates. The shape of resinate affects the flow and 
packing properties & was found to be irregular for Indion 
244 resin and resinate. Angle of repose was found to lie 
between 20-30 °C thus exhibiting good flow properties. 
Bulk density less than 1.2 gm/cm3 exhibited good packing 
ability. Thus the results showed that resin and resinate 
FIGURE 1 - [A] Modified perfusion apparatus in dissolution 
vessel. [B] Modified perfusion apparatus.
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exhibit good flow properties. Carr’s compressibility in-
dex i.e. % compressibility, and Hausner ratio indicate the 
packing ability of powders. 
When compressibility index ranges from 5 to 16 and 
the Hausner ratio approaches 1 the material has good flow 
property and packing ability.
X-ray diffraction
The X–ray diffraction pattern (Figure 2) for drugs 
[A & D] contained a number of sharp peaks, while the 
resins [B & E] showed a diffused peak or halo pattern, 
where as only a diffused peak was observed in X–ray 
powder diffraction patterns for the resinates regardless of 
drug loading. 
According to this data, the molecular state of 
drugs [A&D] was crystalline, but that of resins [B&E] 
was amorphous. The molecular state of drugs prepared 
as drug resin complexes was changed from crystalline 
state to amorphous state. This shows that entrapped drug 
molecules are monomolecularly dispersed in resin beads 
(Pisal et al. 2004). 
TABLE II - Physical properties of resins and resinates
Parameter Indion 244 Resin Domperidone Resinate Indion 294 Resin Ranitidine Resinate
Shape Irregular Irregular Irregular Irregular
Angle of repose 26.56 24.22 25.34 27.21
Bulk density 0.681 0.550 0.625 0.584
Tap density 0.789 0.610 0.731 0.652
Carr’s index 15.85 13.27 16.96 11.64
Housner ratio 1.15 0.98 1.16 0.98
FIGURE 2 - X- ray powder diffraction pattern for A. Domperidone, B. Indion 244, C. Domperidone resinate, D. Ranitidine HCl, 
E.  Indion 294, F. Ranitidine resinate.
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FT-IR STUDIES
The IR spectra for the drugs (Figure 3) [A&D] sho-
ws peak at 3349 cm-1 corresponding to N-H stretching in 
a secondary amine. The absence of a peak at 3349 cm-1 in 
resinates [C&F] confirms the complexation of the secon-
dary amine group in the drugs [A&D] with resins [B&E]. 
The in-vitro dissolution profile (Table III) shows that 
about 43.41% of domperidone was released in 60 min from 
resinate, and about 97.83% of domperidone was released 
FIGURE 3 - Infrared spectra for A. Domperidone, B. Indion 244, C. Domperidone resinate, D. Ranitidine HCl, E.  Indion 294, F. 
Ranitidine resinate.
TABLE III - In-vitro drug release profiles of ranitidine HCl and domperidone from resinates
% Drug Release For Ranitidine % Drug Release For Domperidone
Time (min) % Drug Release Time (min) % Drug Release
5 39.42±0.28 60 43.41±0.36
10 52.28±0.43 120 53.30±0.24
20 61.27±0.25 180 65.95±0.18
30 68.60±0.36 240 67.31± 0.22
40 71.99±0.41 300 71.10±0.16
60 80.14±0.38 360 73.41±0.29
75 87.70±0.29 420 78.05±0.22
90 97.72±0.73 480 84.17±0.41
-- -- 540 88.49±0.31
-- -- 600 93.52±0.33
-- -- 660 97.83±0.46
(Mean ± SD, n=3)
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at the end of 660 min from resinate. The resinate showed 
initial high release but could retard the drug release beyond 
480 min, therefore resinate of a 1:1 ratio showed potential 
to sustain the release of domperidone. The initial burst 
release may be attributed to lower particle size of resinate. 
(Borodkin et al., 1991). The ranitidine release from raniti-
dine resinate was found to be 97.72% in 90 min.
A difference was observed between domperidone 
release from individual domperidone resinate & combina-
tion with ranitidine resinate (Figure 4), where the release 
was retarded from combination. Similar observations are 
reported in the literature (Hughes, 2002)
This can be explained as follows, after complete 
release of ranitidine from resinate, the weak resin was 
available as unloaded resin as it is experimentally demons-
trated that the drug release is retarded in the presence of 
unloaded resin. 
Assay of prepared tablets
FIGURE 4- In-vitro ranitidine & domperidone release from 
combination of resinates.   % release of ranitidine;  % release 
of domperidone.
TABLE IV - Evaluation of prepared tablets
Hardness 
kg/cm2
Thickness 
(mm)
Weight 
uniformity+ 
(mg)
% Friability
5±0.25 4.49 600±0.5 0.7±0.43
 (Mean ± SD, n=3)
In-vitro drug release profile of combination tablet 
and marketed tablet
The results show that the formulated tablet released 
94.05 % domperidone in 11 hours while the marketed 
tablet showed 98.24 % domperidone release in 10 hours 
(Figure 5). Thus, the formulated tablet showed better 
sustained release of domperidone than the marketed 
tablet. The f
2 
value of the domperidone release from the 
combination tablet was found to be 83, comparable to the 
marketed tablet, showing that the formulated tablet had 
a similar release profile as that of the marketed tablet.
In the case of ranitidine hydrochloride formulated 
tablets, the release was 99.45 % drug in 90 min while the 
marketed tablet showed 94.43 % ranitidine hydrochlo-
ride release in 90 min. Thus, there was no significant 
difference in release of ranitidine hydrochloride from 
formulated & marketed tablets. The f
2 
value of the rani-
tidine release from the combination tablet was found to 
be 58.5, compared to the marketed tablet, showing that 
formulated tablet had a similar release profile as that of 
the marketed tablet.
FIGURE 5 - In-vitro dissolution for domperidone from 
formulated and marketed tablet.   Formulated tablet; 
 Marketed tablet
TABLE V - Assay analysis of prepared tablets
Sr.No. Label claim 
(μg/mL)
Amount found 
(μg/mL)
% of label 
claim
RAN DOM RAN DOM RAN DOM
1 5 0.2 5.02 0.199 100.4 99.5
2 5 0.2 4.93 0.198 98.8 98.6
3 5 0.2 4.91 0.199 99.4 99.5
4 5 0.2 5.01 0.202 100.2 101
5 5 0.2 4.99 0.201 98.8 100.5
FIGURE 6 - In-vitro dissolution for ranitidine HCl from 
formulated and marketed tablet.   Formulated tablet; 
 Marketed tablet.
Novel ion exchange resin-based combination drug-delivery system for treatment of gastro esophageal reflux diseases 341
Ex-vivo study for absorption through everted rat 
intestine
Data presented in Table VI represents the amount of 
domperidone & ranitidine transported across everted rat 
intestine, expressed as percent of amount of drugs released 
in-vitro over the time interval. Data suggest that there is 
no difference in ex-vivo drug absorption from marketed 
and prepared combination tablet.
The data was subjected to paired t test using Instat3.0 
software. The mean of the differences between column A 
and column B was found not to differ significantly from 
zero. The one-tailed P value was 0.3041, considered non-
significant at a 95% confidence interval.
By applying statistical treatment to the above data it 
was concluded that absorption of ranitidine hydrochloride 
and domperidone from formulated & marketed tablets did 
not differ significantly from each other.
CONCLUSION
Gastric acid inhibitors such as ranitidine HCl, and 
prokinetic agents such as domperidone, are known to 
enhance gastrointestinal motility and prevent duodenogas-
tric reflux, and are widely used to treat gastro esophageal 
reflux diseases (GERDs). Hence, a combination of imme-
diate release ranitidine and sustained release domperidone 
in a unit dosage form will be a useful therapeutic option, 
enhancing patient compatibility and therapeutic benefit.  
Formulated tablet provided pH independent sus-
tained release of domperidone, and fast release of rani-
tidine. Ex-vivo studies suggest that there is no difference 
TABLE VI - Ex-vivo study for absorption through everted rat intestine
Time (h) % Drug Absorbed
From formulated tablet From marketed tablet
Ranitidine 
hydrochloride
Domperidone Ranitidine 
hydrochloride
Domperidone
0.5 67.23±1.23 24.56±0.68 72.64±0.25 15.20±0.49
1 73.44±0.67 25.68±0.29 77.50±0.65 18.27±0.69
2 81.63±0.72 26.36±0.89 79.71±0.81 27.34±0.83
3 -- 32.04±0.78 -- 33.46±0.79
4 -- 36.83±0.64 -- 36.66±0.91
5 -- 37.41±0.69 -- 38.53±0.48
6 -- 37.88±0.73 -- 41.16±0.77
7 -- 43.45±0.75 -- 44.38±0.59
8 -- 49.37±0.71 -- 49.58±0.82
(Mean ± SD, n=3)
in ex-vivo drug absorption from marketed and prepared 
combination tablet. 
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